

ZLN005

Catalog No: tcsc2189



Available Sizes

Size: 10mg

Size: 50mg



Specifications

CAS No:

49671-76-3

Formula:

$C_{17}H_{18}N_2$

Pathway:

Metabolic Enzyme/Protease

Target:

PGC-1 α

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 47 mg/mL (187.74 mM)

Observed Molecular Weight:

250.34

Product Description


ZLN005 is a novel transcriptional regulator of peroxisome proliferator-activated receptor- γ coactivator-1 α (PGC-1 α).

IC50 value:

Target: PGC-1 α

in vitro: ZLN005 increases expression of the PGC-1 α gene in L6 myotubes. ZLN005 increased PGC-1 α mRNA levels in a dose-dependent manner; 20 μ mol/L ZLN005 caused a threefold increase over the control after 24 h. At 10 μ mol/L, the PGC-1 α mRNA levels were increased to almost the same extent at 16 to 48 h [1]. ZLN005 did not increase the expression of the PGC-1 α gene in rat primary hepatocytes. AMP-activated protein kinase is involved in the mechanism inducing PGC-1 α in L6 myotubes [1]

in vivo: An insulin tolerance test revealed that treatment with ZLN005 significantly decreased insulin resistance in db/db mice, as evidenced by the approximately 18% decrease in the AUC. A PTT also was performed in db/db mice, and ZLN005 improved pyruvate tolerance, as evidenced by the 16% decrease in the AUC. In db/db mice, plasma NEFA and triglyceride levels were decreased by 20% and 37%, respectively, and cholesterol was decreased by 10% with ZLN005 treatment. Plasma insulin and β -hydroxybutyrate content, liver/bodyweight index and adipose composition, and muscle and liver triglyceride levels, however, were not ameliorated by treatment with ZLN005 or metformin [1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!